Breaking News

Tweet TWEET

Amarin Announces Issuance of U.S. Patents 8,793,727 and 8,293,728 for Vascepa(TM)

Amarin Announces Issuance of U.S. Patents 8,793,727 and 8,293,728 for
Vascepa(TM)

Issuances for '889 and '153 Applications

BEDMINSTER, N.J. and DUBLIN, Ireland, Oct. 23, 2012 (GLOBE NEWSWIRE) -- Amarin
Corporation plc (Nasdaq:AMRN), a biopharmaceutical company focused on the
commercialization and development of therapeutics to improve cardiovascular
health, announced today that the U.S. Patent and Trademark Office (USPTO) has
issued two patents covering the use of Amarin's Vascepa^TM (icosapent ethyl)
capsules based on U.S. Patent Application Serial Nos. 12/702,889 and
13/349,153, both titled "Methods of Treating Hypertriglyceridemia." On
September 5, 2012, Amarin announced the issuance of Notices of Allowance for
claims under these applications.

The newly issued patents, U.S. Patent Numbers 8,793,727 and 8,293,728, have
patent terms that each expire no earlier than in 2030. Amarin plans to list
both patents in the U.S. Food and Drug Administration's Approved Drug Products
with Therapeutic Equivalence Evaluations, or Orange Book.

"These patent issuances represent another step forward in Amarin's effort to
protect the commercial potential of Vascepa," said Joseph Zakrzewski, Amarin's
Chairman and Chief Executive Officer. "Amarin's goal is to protect the
commercial potential of Vascepa to beyond 2030 through patent protection,
regulatory exclusivity and trade secrets and by taking advantage of
manufacturing barriers to entry."

Amarin now has eight U.S. patents either issued or allowed as well as over 30
additional patent applications currently in prosecution in the United States.
Amarin is also pursuing patent applications related to Vascepa in multiple
jurisdictions outside the United States, including the application for
Amarin's MARINE method of use patent in Europe for which Amarin has announced
receipt of an Intention to Grant letter.

About Amarin

Amarin Corporation plc is a biopharmaceutical company focused on the
commercialization and development of therapeutics to improve cardiovascular
health. Amarin's product development program leverages its extensive
experience in lipid science and the potential therapeutic benefits of
polyunsaturated fatty acids. Vascepa^TM (icosapent
ethyl),Amarin'sfirstFDAapproved product, is a patented, ultra pure omega-3
fatty acid product comprising not less than 96%EPA.For more information
about Vascepa visit www.vascepa.com. For more information about Amarin visit
www.amarincorp.com.

The Amarin Corporation plc logo is available at
http://www.globenewswire.com/newsroom/prs/?pkgid=13817

Forward-looking statements

This press release contains forward-looking statements, including statements
about whether certain issued patents would adequately protect Vascepa against
competition, Amarin's plan to protect the commercial potential of Vascepa, and
the future status of patent applications under review by the United States
Patent and Trademark Office.These forward-looking statements are not promises
or guarantees and involve substantial risks and uncertainties. Among the
factors that could cause actual results to differ materially from those
described or projected herein include the following: events that could
interfere with the continued validity or enforceability of a patent or the
issuance of a patent if not yet issued; Amarin'sability generally to
maintain adequate patent protection and successfully enforce patent claims
against third parties; commercializing Vascepa without violating the
intellectual property rights of others;and uncertainties associated generally
with research and development, clinical trials and related regulatory
approvals and exclusivity grants. A further list and description of these
risks, uncertainties and other risks associated with an investment in Amarin
can be found in Amarin's filings with the U.S. Securities and Exchange
Commission, including its most recent Quarterly Report on Form 10-Q.Existing
and prospective investors are cautioned not to place undue reliance on these
forward-looking statements, which speak only as of the date hereof. Amarin
undertakes no obligation to update or revise the information contained in this
press release, whether as a result of new information, future events or
circumstances or otherwise.

CONTACT: Investor Contact Information:
         Stephen D. Schultz
         Senior Director, Investor Relations
         and Corporate Communications
         Amarin Corporation
         In U.S.: +1 (860) 572-4979 x292
         investor.relations@amarincorp.com
        
         Lee M. Stern
         The Trout Group
         In U.S.: +1 (646) 378-2922
         lstern@troutgroup.com
        
         Media Contact Information:
         David Schull or Martina Schwarzkopf, Ph.D.
         Russo Partners
         In U.S.: +1 (212) 845-4271
         or +1 (212) 845-4292 (office)
         +1 (347) 591-8785 (mobile)
         david.schull@russopartnersllc.com
         martina.schwarzkopf@russopartnersllc.com

company logo
 
Press spacebar to pause and continue. Press esc to stop.